OTTAWA, May 09, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased to
announce that Raphael Mechoulam has agreed to extend his role as an advisor to the Company.
Mechoulam is an Israeli Organic Chemist, and a professor at the Hebrew University of Jerusalem’s Medical
Faculty, Institute for Drug Research. Professor Mechoulam has been nominated for the Nobel Prize, and is often regarded as the
"Father of Marijuana Research."
Professor Mechoulam has been a pioneer in medicinal cannabis research for more than five decades. His most
significant cannabis research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963 which led to
isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and elucidating the structure of the brain's first
endogenous cannabinoid, Anandamide, in 1992.
“Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most
aggressive growth stage in the company’s history. The Company has invested heavily to build and extend its early leadership in
advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has
played a major role in achieving this, says Aaron Keay CEO and Director of ABcann.
“I have followed the development of cannabis for medical use for many years. There is no doubt that it is very
helpful in numerous diseases, however many physicians refrain from prescribing it. I believe that the route followed by ABcann for
standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will
also make possible clinical trials which will develop the evidence to transform how cannabis is perceived by the pharmaceutical
industry and the regulatory agencies” said Professor Mechoulam.
“The Professor’s agreement to extend his relationship with ABcann is one of the strongest votes of confidence our
company could ever receive,” says Ken Clement, Founder and Executive Chairman of ABcann.
ON BEHALF OF THE BOARD OF DIRECTORS OF ABCANN GLOBAL CORPORATION
“Aaron Keay”
Aaron Keay
Director
For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at aaron@abcannglobal.com OR Leo Karabelas by phone (416) 543-3120 or by email at leo.k@abcannglobal.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this release are forward-looking statements, which reflect the expectations of management
regarding the proposed Qualifying Transaction, the Concurrent Financings and ABcann’s future business plans. Forward-looking
statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or
intentions regarding the future. Forward looking statements in this news release include statements relating to: the terms of the
Transaction; the terms of the Concurrent Financings and the use of proceeds thereof; the consistency of ABcann’s product; and
ABcann’s future site development and expansion plans. Such statements are subject to risks and uncertainties that may cause actual
results, performance or developments to differ materially from those contained in the statements, including that: the TSXV may not
approve the Transaction; the Transaction may not be completed for any other reason; the Concurrent Financings may not be completed
on the terms contemplated or at all; the proceeds of the Concurrent Financings may not be allocated as currently contemplated; or
factors may occur which cause ABcann’s currently contemplated expansion and development plans to cease or otherwise change. No
assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what
benefits the Company or the Resulting Issuer will obtain from them. Readers are urged to consider these factors carefully in
evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such
forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements
are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking
statements, whether as a result of new information, future events or results or otherwise, except as required by applicable
securities laws.
